Library · Brain & nerves · Treatment of small fiber neuropathy and nerve protection

ARA-290 (Cibinetide)

Cibinetide, ARA290, ARA 290, Helix B surface peptide

11-amino-acid peptide derived from erythropoietin that activates the innate repair receptor for tissue protection without stimulating red blood cell production. Holds FDA orphan status for sarcoidosis and islet-transplant survival; completed a Phase 2 trial in diabetic macular edema, with preclinical work in neuropathy, Alzheimer’s, and drug-induced kidney injury.

Research score 70/100. Reference only, not a dose.

• Neuroprotective
• Anti-inflammatory
• Pain Relief
• Healing
• Neuroprotection

US status

Investigational

Approval

Phase 2 Clinical Trial (Completed). Granted orphan drug designation for sarcoidosis and pancreatic islet transplantation.

Evidence

Phase 2 clinical trial for Diabetic Macular Edema completed. Extensive preclinical research shows neuroprotection, organ protection (e.g., against cisplatin-induced nephrotoxicity, 2022), and potential to ameliorate frailty in mouse models.

Research score

70 / 100

Indication

Investigational - Small Fiber Neuropathy, Sarcoidosis

Origin

USA

Source category

Brain & Nervous System

Status group

Investigational